Skip to main content
. Author manuscript; available in PMC: 2011 Jul 27.
Published in final edited form as: Transplantation. 2010 Jul 27;90(2):189–197. doi: 10.1097/TP.0b013e3181e2a932

Table 2.

Clinical and Histological Parameters of BKVN Patients

BKVN-DFa
N=8 (%)
BKVN-SFa
N=10 (%)
P Valueb
Baseline Parameters
Age (mean± SD) 52± 6 51 ±13 0.85
Gender (% male) 8 (100%) 5 (50%) 0.04
Deceased Donor grafts (%) 4(50%) 7 (70%) 0.63
ATG induction (%) 3 (38%) 5 (50%) 0.66
Steroid Maintenance (%) 4 (50%) 6 (60%) 1.0
Biopsy Creatinine
(mean±SD)
2.79±0.5 2.03±0.7 0.02
Time from Transplant to
Biopsy (Months, mean±SD)
11.6±10.4 11.7±6.5 0.51
Histological Grades &
Scores (mean±SD)
PVAN Grade 3 A, 6 A , 0.41c
(Drachenberg Stage [15]) 2 B, 2 B,
3 C 2 C
Cytopathic score 1.4±0.26 1.5 ± 0.27 0.75
Tubulitis score 1.3±0.25 1.1±0.32 0.73
Infiltrate score 1.9±0.4 1.6±0.4 0.64
Tubular atrophy score 1.8±041 1.1±0.23 0.17
Interstitial Fibrosis score 1.25±0.31 0.8±0.13 0.17
BKVN Treatment
IVIG Therapy (%) 4 (50%) 8 (80%) 0.32
Leflunomide Therapy (%) 3 (38%) 6 (60%) 0.64
a

The BKVN patients with an increase in the level of serum creatinine of ≥0.5mg/dl during the one-year following BKVN diagnosis were classified as the Decline in Function Group (BKVN-DF) and the BKVN patients without such an increase were classified as the Stable Function Group (BKVN-SF).

b

Categorical variables were compared using Fisher’s Exact Test; Continuous variables were compared using Mann Whitney Test

c

PVAN grades were compared using Jonckheere-Terpstra Exact test for Trend.